 Omar Khan
Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bariatric Surgery | 7 | 2023 | 245 | 2.820 |
Why?
| | Obesity, Morbid | 6 | 2023 | 288 | 1.330 |
Why?
| | Gastrectomy | 5 | 2023 | 162 | 0.800 |
Why?
| | Global Health | 2 | 2016 | 401 | 0.680 |
Why?
| | Gastric Bypass | 4 | 2023 | 126 | 0.560 |
Why?
| | Prejudice | 1 | 2017 | 61 | 0.510 |
Why?
| | Health Care Costs | 1 | 2020 | 425 | 0.510 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 300 | 0.490 |
Why?
| | International Educational Exchange | 1 | 2016 | 10 | 0.480 |
Why?
| | Carcinoma, Renal Cell | 3 | 2023 | 234 | 0.460 |
Why?
| | Physicians, Primary Care | 1 | 2017 | 209 | 0.440 |
Why?
| | Fractures, Bone | 1 | 2020 | 417 | 0.430 |
Why?
| | Attitude to Health | 1 | 2017 | 431 | 0.420 |
Why?
| | Kidney Neoplasms | 3 | 2023 | 412 | 0.410 |
Why?
| | Maternal Death | 1 | 2013 | 15 | 0.390 |
Why?
| | Education, Medical, Undergraduate | 1 | 2016 | 205 | 0.390 |
Why?
| | Obesity | 4 | 2023 | 3070 | 0.380 |
Why?
| | Maternal Health Services | 1 | 2013 | 102 | 0.350 |
Why?
| | Schools, Medical | 1 | 2013 | 158 | 0.340 |
Why?
| | Quality Assurance, Health Care | 1 | 2013 | 341 | 0.340 |
Why?
| | Hypoglycemic Agents | 1 | 2020 | 1388 | 0.330 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2573 | 0.310 |
Why?
| | Insulin | 1 | 2020 | 2502 | 0.300 |
Why?
| | Kidney Transplantation | 1 | 2016 | 709 | 0.300 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1180 | 0.300 |
Why?
| | Registries | 5 | 2023 | 2392 | 0.290 |
Why?
| | Weight Loss | 4 | 2023 | 839 | 0.290 |
Why?
| | Endpoint Determination | 1 | 2009 | 84 | 0.290 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1056 | 0.280 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2009 | 133 | 0.280 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2009 | 82 | 0.270 |
Why?
| | Health Promotion | 1 | 2013 | 771 | 0.250 |
Why?
| | United Kingdom | 4 | 2023 | 337 | 0.240 |
Why?
| | Pelizaeus-Merzbacher Disease | 1 | 2006 | 3 | 0.240 |
Why?
| | RNA, Small Interfering | 4 | 2019 | 631 | 0.230 |
Why?
| | Neuromyelitis Optica | 2 | 2017 | 137 | 0.210 |
Why?
| | Endothelium, Vascular | 2 | 2021 | 949 | 0.200 |
Why?
| | Humans | 28 | 2023 | 144667 | 0.190 |
Why?
| | Gastrointestinal Hormones | 1 | 2021 | 5 | 0.170 |
Why?
| | Iron-Binding Proteins | 1 | 2021 | 43 | 0.170 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 122 | 0.160 |
Why?
| | Multiple Sclerosis | 3 | 2010 | 485 | 0.160 |
Why?
| | Cost Savings | 1 | 2020 | 85 | 0.160 |
Why?
| | Models, Economic | 1 | 2020 | 61 | 0.160 |
Why?
| | Postprandial Period | 1 | 2021 | 114 | 0.160 |
Why?
| | Friedreich Ataxia | 1 | 2021 | 78 | 0.150 |
Why?
| | Bile Acids and Salts | 1 | 2021 | 163 | 0.150 |
Why?
| | Drug Costs | 1 | 2020 | 117 | 0.150 |
Why?
| | Vascular Remodeling | 1 | 2021 | 203 | 0.150 |
Why?
| | Cellular Senescence | 1 | 2021 | 223 | 0.140 |
Why?
| | Hypertension, Pulmonary | 2 | 2021 | 1948 | 0.140 |
Why?
| | Gastroplasty | 1 | 2018 | 32 | 0.140 |
Why?
| | Glycine | 1 | 2019 | 186 | 0.130 |
Why?
| | Bayes Theorem | 1 | 2020 | 426 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 638 | 0.130 |
Why?
| | England | 1 | 2017 | 108 | 0.130 |
Why?
| | Treatment Failure | 1 | 2018 | 365 | 0.130 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 262 | 0.120 |
Why?
| | Diabetes Complications | 1 | 2018 | 223 | 0.120 |
Why?
| | Adult | 9 | 2023 | 40489 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2023 | 11735 | 0.120 |
Why?
| | Gastroesophageal Reflux | 1 | 2018 | 236 | 0.120 |
Why?
| | Middle Aged | 6 | 2023 | 35971 | 0.120 |
Why?
| | Capacity Building | 1 | 2016 | 62 | 0.110 |
Why?
| | Cultural Competency | 1 | 2016 | 89 | 0.110 |
Why?
| | Female | 12 | 2023 | 78304 | 0.110 |
Why?
| | Reoperation | 1 | 2018 | 624 | 0.110 |
Why?
| | Dextrans | 1 | 2015 | 86 | 0.110 |
Why?
| | Databases, Factual | 1 | 2020 | 1494 | 0.110 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2015 | 60 | 0.110 |
Why?
| | Weight Gain | 1 | 2018 | 557 | 0.100 |
Why?
| | Developing Countries | 1 | 2016 | 317 | 0.100 |
Why?
| | Male | 10 | 2023 | 72431 | 0.100 |
Why?
| | Brain | 1 | 2006 | 2934 | 0.100 |
Why?
| | Gene Silencing | 1 | 2014 | 202 | 0.100 |
Why?
| | Antibodies | 1 | 2015 | 396 | 0.090 |
Why?
| | Nanostructures | 1 | 2014 | 110 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2016 | 399 | 0.090 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 852 | 0.090 |
Why?
| | Graft Rejection | 1 | 2016 | 512 | 0.090 |
Why?
| | Patient Readmission | 1 | 2018 | 765 | 0.090 |
Why?
| | Gene Expression | 2 | 2014 | 1476 | 0.090 |
Why?
| | Length of Stay | 1 | 2018 | 1339 | 0.090 |
Why?
| | International Cooperation | 1 | 2013 | 197 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2023 | 990 | 0.090 |
Why?
| | Cohort Studies | 2 | 2021 | 5957 | 0.090 |
Why?
| | Pilot Projects | 1 | 2017 | 1886 | 0.090 |
Why?
| | Transfection | 1 | 2014 | 924 | 0.090 |
Why?
| | Program Evaluation | 1 | 2016 | 941 | 0.090 |
Why?
| | Social Environment | 1 | 2013 | 253 | 0.090 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 380 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2017 | 852 | 0.090 |
Why?
| | Laparoscopy | 1 | 2016 | 477 | 0.080 |
Why?
| | Myocardium | 1 | 2016 | 928 | 0.080 |
Why?
| | Immunologic Factors | 2 | 2010 | 259 | 0.080 |
Why?
| | Age Factors | 1 | 2017 | 3329 | 0.080 |
Why?
| | Time Factors | 1 | 2020 | 7140 | 0.080 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 134 | 0.070 |
Why?
| | Hypertension | 1 | 2018 | 1262 | 0.070 |
Why?
| | Education, Medical | 1 | 2013 | 273 | 0.070 |
Why?
| | Major Histocompatibility Complex | 1 | 2010 | 233 | 0.070 |
Why?
| | Neuroprotective Agents | 1 | 2010 | 145 | 0.070 |
Why?
| | Sample Size | 1 | 2009 | 120 | 0.070 |
Why?
| | Lipids | 1 | 2014 | 706 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2016 | 2489 | 0.070 |
Why?
| | Research Design | 1 | 2015 | 1129 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1961 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1360 | 0.070 |
Why?
| | Macrophages | 1 | 2016 | 1496 | 0.070 |
Why?
| | Quality of Life | 1 | 2020 | 3183 | 0.070 |
Why?
| | MicroRNAs | 1 | 2014 | 689 | 0.070 |
Why?
| | Stroke | 1 | 2017 | 1262 | 0.070 |
Why?
| | Genome, Human | 1 | 2010 | 420 | 0.070 |
Why?
| | Secondary Prevention | 1 | 2009 | 255 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 368 | 0.060 |
Why?
| | Primary Health Care | 1 | 2017 | 1730 | 0.060 |
Why?
| | United States | 2 | 2016 | 16018 | 0.060 |
Why?
| | Fabry Disease | 1 | 2006 | 2 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2023 | 17149 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5870 | 0.060 |
Why?
| | Prospective Studies | 1 | 2018 | 7994 | 0.060 |
Why?
| | Curriculum | 1 | 2013 | 1063 | 0.060 |
Why?
| | Demyelinating Diseases | 1 | 2006 | 84 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2018 | 2950 | 0.060 |
Why?
| | Mice | 6 | 2021 | 18261 | 0.060 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 669 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2019 | 4110 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2019 | 5967 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2019 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2010 | 2350 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2010 | 3414 | 0.050 |
Why?
| | Myelin Sheath | 1 | 2006 | 169 | 0.050 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2660 | 0.050 |
Why?
| | State Medicine | 1 | 2023 | 26 | 0.050 |
Why?
| | Anilides | 1 | 2023 | 84 | 0.050 |
Why?
| | Heart Failure | 1 | 2016 | 2324 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2010 | 2815 | 0.040 |
Why?
| | Aged | 2 | 2022 | 25955 | 0.040 |
Why?
| | Endothelial Progenitor Cells | 1 | 2021 | 20 | 0.040 |
Why?
| | Bevacizumab | 1 | 2022 | 168 | 0.040 |
Why?
| | Chenodeoxycholic Acid | 1 | 2021 | 12 | 0.040 |
Why?
| | Ursodeoxycholic Acid | 1 | 2021 | 17 | 0.040 |
Why?
| | Secretory Pathway | 1 | 2021 | 8 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2021 | 3109 | 0.040 |
Why?
| | Animals | 6 | 2021 | 37948 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2021 | 215 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2022 | 242 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2016 | 2184 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2022 | 550 | 0.040 |
Why?
| | Cell Respiration | 1 | 2019 | 105 | 0.040 |
Why?
| | Pyridines | 1 | 2023 | 603 | 0.040 |
Why?
| | Iron-Sulfur Proteins | 1 | 2019 | 47 | 0.040 |
Why?
| | Haplotypes | 2 | 2010 | 495 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2021 | 605 | 0.030 |
Why?
| | Administration, Oral | 1 | 2021 | 851 | 0.030 |
Why?
| | Eating | 1 | 2021 | 388 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2022 | 2033 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2016 | 84 | 0.030 |
Why?
| | Mutation | 2 | 2019 | 4081 | 0.030 |
Why?
| | RNAi Therapeutics | 1 | 2015 | 6 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2847 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1078 | 0.030 |
Why?
| | RNA, Neoplasm | 1 | 2014 | 83 | 0.030 |
Why?
| | Triazines | 1 | 2014 | 49 | 0.030 |
Why?
| | HIV | 1 | 2015 | 248 | 0.020 |
Why?
| | ras Proteins | 1 | 2014 | 151 | 0.020 |
Why?
| | Nanotechnology | 1 | 2014 | 121 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 254 | 0.020 |
Why?
| | Young Adult | 2 | 2021 | 14122 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1501 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 306 | 0.020 |
Why?
| | Cisplatin | 1 | 2014 | 339 | 0.020 |
Why?
| | HeLa Cells | 1 | 2014 | 632 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2015 | 498 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1268 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 619 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2010 | 18 | 0.020 |
Why?
| | Allelic Imbalance | 1 | 2010 | 9 | 0.020 |
Why?
| | INDEL Mutation | 1 | 2010 | 20 | 0.020 |
Why?
| | Calcineurin Inhibitors | 1 | 2010 | 69 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2014 | 532 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1810 | 0.020 |
Why?
| | Interferon-beta | 1 | 2010 | 92 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 161 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 109 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 249 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2015 | 875 | 0.020 |
Why?
| | Breast | 1 | 2010 | 157 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 220 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2010 | 184 | 0.020 |
Why?
| | Heterozygote | 1 | 2010 | 313 | 0.020 |
Why?
| | Genetics, Population | 1 | 2010 | 215 | 0.020 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 245 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4539 | 0.020 |
Why?
| | Nanoparticles | 1 | 2014 | 512 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2010 | 374 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5414 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 613 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2014 | 923 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 886 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2015 | 1984 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3523 | 0.020 |
Why?
| | Adolescent | 2 | 2019 | 22409 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1186 | 0.010 |
Why?
| | DNA Methylation | 1 | 2010 | 664 | 0.010 |
Why?
| | Infant | 1 | 2019 | 10023 | 0.010 |
Why?
| | Peptides | 1 | 2010 | 989 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8284 | 0.010 |
Why?
| | Child, Preschool | 1 | 2019 | 11790 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 1129 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2201 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2137 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2010 | 3603 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 3148 | 0.010 |
Why?
| | Child | 1 | 2019 | 22600 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2010 | 2365 | 0.010 |
Why?
| | Lung | 1 | 2010 | 4089 | 0.010 |
Why?
|
|
Khan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|